Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/transthera-announced-global-phase-3-clinical-trial-for-cholangiocarcinoma-authorized-in-the-european-union-and-orphan-drug-designation-for-tinengotinib-to-treat-biliary-tract-cancer-granted-by-european-medicines-agency-302084086.html
https://www.prnewswire.com/news-releases/transthera-initiates-ind-enabling-studies-for-tt-02332-a-novel-highly-potent-and-cns-penetrating-nlrp3-inhibitor-302070999.html
https://www.prnewswire.com/news-releases/transthera-announces-the-global-multicenter-phase-3-clinical-trial-completed-first-patient-dosing-in-the-us-evaluating-tinengotinib-in-fgfri-relapsedrefractory-patients-with-cholangiocarcinoma-302021004.html
https://www.prnewswire.com/news-releases/2023-sabcs---transthera-announces-an-oral-presentation-of-tinengotinib-clinical-data-in-breast-cancer-302008583.html
https://www.prnewswire.com/news-releases/transthera-announces-two-oral-presentations-of-tinengotinib-clinical-data-at-2023-esmo-and-sabcs-annual-meetings-301950709.html
https://www.pharmaceutical-technology.com/news/fda-transthera-b-cell-lymphoma/
https://www.prnewswire.com/news-releases/transthera-announces-that-the-ind-application-of-tt-01488-a-non-covalent-reversible-btk-inhibitor-for-the-treatment-of-b-cell-lymphomas-has-been-approved-by-the-fda-in-the-us-and-officially-accepted-by-the-nmpa-in-china-301485640.html
https://en.prnasia.com/releases/global/transthera-announces-collaboration-with-roche-to-evaluate-tt-00420-as-part-of-a-novel-combination-to-treat-gi-cancers-in-china-319994.shtml
https://www.prnewswire.com/news-releases/transthera-announces-collaboration-with-roche-to-evaluate-tt-00420-as-part-of-a-novel-combination-to-treat-gi-cancers-in-china-301299701.html
https://www.prnewswire.com/news-releases/transthera-announces-collaboration-with-roche-to-evaluate-tt-00420-as-part-of-a-novel-combination-to-treat-gi-cancers-in-china-301299701.html